

PATRICK J. LEAHY, VERMONT, CHAIRMAN

HERB KOHL, WISCONSIN
DIANNE FEINSTEIN, CALIFORNIA
CHARLES E. SCHUMER, NEW YORK
RICHARD J. DURBIN, ILLINOIS
SHELDON WHITEHOUSE, RHODE ISLAND
AMY KLOBUCHAR, MINNESOTA
AL FRANKEN, MINNESOTA
CHRISTOPHER A. COONS, DELAWARE
RICHARD BLUMENTHAL, CONNECTICUT

CHARLES E. GRASSLEY, IOWA
ORRIN G. HATCH, UTAH
JON KYL, ARIZONA
JEFF SESSIONS, ALABAMA
LINDSEY O. GRAHAM, SOUTH CAROLINA
JOHN CORNYN, TEXAS
MICHAEL S. LEE, UTAH
TOM COBURN, OKLAHOMA

United States Senate

COMMITTEE ON THE JUDICIARY

WASHINGTON, DC 20510-6275

BRUCE A. COHEN, *Chief Counsel and Staff Director*
KOLAN L. DAVIS, *Republican Chief Counsel and Staff Director*

May 4, 2011

Via Electronic Transmission

John Walter
President and Chief Executive Officer
The Leukemia & Lymphoma Society
1311 Mamaroneck Avenue, Suite 310
White Plains, NY 10605

Dear Mr. Walter:

In December 2009, I asked for an accounting of industry funding that The Leukemia & Lymphoma Society (LLS) receives from pharmaceutical and medical device companies as well as foundations established by these companies or the insurance industry. I appreciate your response, which I have attached to this letter. I write today to follow up on any efforts by your organization to improve transparency and accountability in its relationships with the pharmaceutical and device industries.

As I stated in my previous letter, I started my inquiry, in part, as a result of accounts documenting the lack of transparency in financial relationships between the pharmaceutical industry and nonprofit health and medical organizations. Specifically, I cited the April 2008 article in *The Wall Street Journal*, which reported that industry representatives, including ten major drug companies, had formed a coalition to promote looser restrictions on off-label marketing.¹ The coalition had asked the National Alliance on Mental Illness (NAMI) to speak in favor of this issue.

In response to my concerns in my April 2009 letter to NAMI, NAMI began to voluntarily disclose to the public any amount of funding exceeding \$5,000 that it received from pharmaceutical companies and foundations on its website. Further, NAMI began to provide a brief description of the purpose of the funding on its website. I commend NAMI for its leadership and had hoped that when I reached out to your organization and 32 others, your organization would follow NAMI's example and begin posting similar funding information on LLS's website.

As of the date of this letter, it appears that your organization has taken steps to identify on its website the corporate or industry sponsors and their range of funding support. However, the website does not specify the purposes of that funding. If LLS is currently taking steps to further

¹ Alicia Mundy, "Off-Label Use of Drugs Gets a Push --- Big Pharma Lobbies Washington to Relax Rules on Marketing," *The Wall Street Journal*, April 18, 2008.

enhance the transparency of its financial relationships with the pharmaceutical and device industries, I would appreciate information regarding those steps. In particular, please state whether or not LLS will be adding information in the future about the purpose of the funding it receives. If not, please explain why not.

The Medicare Payment Advisory Commission (MedPAC) recommended in a report to Congress in March 2009 that Congress require that pharmaceutical and device companies report their financial relationships with physician groups, patient organizations, and others. More specifically MedPAC said the following:

Given the potential benefits of public reporting, we recommend that the Congress mandate the reporting of comprehensive information on industry relationships with physicians and other health care entities and that the Secretary post this information on a public searchable website.²

MedPAC then went on to say in Recommendation 5-1 that:

The Congress should require all manufacturers and distributors of drugs, biologicals, medical devices, and medical supplies (and their subsidiaries) to report to the Secretary their financial relationship with: . . . physician groups and other prescribers . . . patient organizations; and professional organizations.³

I look forward to working with you and other health and medical organizations to further increase sunshine on financial relationships.

Thank you for your cooperation and attention in this matter. I would appreciate a response by May 25, 2011. If you have any questions, please do not hesitate to contact Brian Downey for the Committee on the Judiciary at (202) 224-5225.

Sincerely,



Charles E. Grassley
Ranking Member

Attachments

² Medicare Payment Advisory Commission, "Public reporting of physicians' financial relationships," Report to Congress: Medicare Payment Policy, March 2009.

³ *Id.*

Attachment



John E. Walter

President & CEO

Home Office

1311 Mamaroneck Avenue, White Plains, NY 10605

tel. 914.821.8822 fax. 914.821.3622

email john.walter@lls.org

December 18, 2009

Senator Charles E. Grassley
United States Senator
Ranking Member of the Committee on Finance

Dear Senator Grassley:

The Leukemia & Lymphoma Society (LLS) is pleased to respond to your letter of inquiry dated December 7, 2009 regarding disclosure of industry funding from pharmaceutical, medical device, and insurance companies to medical groups. LLS does receive financial support from pharmaceutical and allied health industries. A full disclosure of this support for the period of 2006-2009 is reported in the attached document. The LLS fiscal year is from July 1- June 30, therefore, the attached tables include reporting for the period from July 1, 2005 – June, 30 2009.

The Leukemia & Lymphoma Society a 501 (c) 3 organization (Tax ID # 135644916) is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than \$680 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 4.9 million contacts with patients, caregivers and healthcare professionals through services provided at its Home Office and 64 chapters in the United States and Canada.

LLS accepts funding from corporate donors, including pharmaceutical, medical device and insurance industries when it identifies companies that will provide unrestricted support for LLS programs, research or fundraising events. Total funding for the period from 2006-2009 was \$54.1 million, roughly 5% of the total LLS revenue for that period. A table detailing this funding is attached. In FY2009 (ending 6/30/09) LLS received a total of \$21.8 million from pharmaceutical, medical device and insurance industries. This amount represented 7.6% of the total LLS 2009 revenue of \$288 million. All funds are in the form of grant requests for educational programs, research and sponsorship for fundraising events. Proposals that are submitted from LLS are reviewed by the corporate grant committees at each company. LLS does not allow corporate donors to influence content, format or delivery of its educational and research programs, nor does it allow any input around the LLS national and local fundraising programs. Support for public policy programs is directed towards education and outreach campaigns that have been developed by LLS staff, free of influence from any corporate donor. This policy is directed by the National Office of The Leukemia & Lymphoma Society and is followed by all LLS chapter offices as well.

LEUKEMIA

LYMPHOMA

MYELOMA

www.lls.org

In the area of support for individual researchers, The LLS Medical & Scientific Affairs Committee, composed of volunteer scientists and physicians, makes the determinations about which researchers will receive support. Industry donations can be directed towards a researcher to whom LLS has already awarded a grant. The corporate donor has no influence on the research award, nor, does it have influence on the LLS researcher who is named to the grant award. The LLS researcher who is supported by a pharmaceutical grant to LLS does not have any relationship with that company. LLS is awarding the funds to the researcher, not the pharmaceutical company. The pharmaceutical company is awarding funds to LLS to support a researcher that is identified by LLS. In some cases, the grant award from a pharmaceutical company does not cover the full cost of the research award to the individual researcher or team of researchers.

The LLS Therapy Acceleration Program (TAP) was launched in fiscal year 2008 to address some of the hurdles associated with blood cancer drug development. The program focuses on efforts that reduce investment risk and accelerate clinical progress. TAP contributes to an end-to-end solution for development of new blood cancer therapies, and is comprised of three innovative strategies to hasten progress: the Academic Concierge Division, the Biotechnology Accelerator Division and the Clinical Trials Division. The Academic Concierge Division identifies LLS-funded research grant projects that have near-term clinical promise and provides the funding and support needed to advance selected projects to the product stage. Through the Biotechnology Accelerator Division, LLS allies with companies to combine scientific and financial resources and accelerate the development of promising therapies for blood cancer patients. Biotechnology companies are the focus of this program because of their reputation for innovation and successful drug development. Historically, pharmaceutical companies have resisted developing blood cancer treatments because they are perceived as having less potential for high reward due to relatively small patient populations. The Biotechnology Accelerator Division funds only projects that are close to generating data on clinical efficacy in blood cancer patients. This ensures that the company will be able to gain additional resources to complete the testing, registration and marketing of new treatments for patients. In the Clinical Trials Division, LLS partners with one or more of the country's leading clinical trial centers to build the infrastructure for broader access to blood cancer clinical trials and significantly increase enrollment of adult cancer patients. Planned is a network of Phase I and II clinical trial sites that will use new strategies to increase patient enrollment, especially among under-represented populations.

Disclosure of pharmaceutical support to LLS is acknowledged in all educational programs and printed materials. Invitations & announcements to live and online programs that have been supported by grant funding from pharmaceutical, medical device and insurance industries acknowledge corporate support and recognition for each program. Sample invitations are attached along with educational publications that show how LLS discloses its corporate donors to the public. Disclosure of all corporate donors and funding levels is listed in the LLS Annual Report, which is distributed to LLS individual, corporate and foundation donors (copy attached). The LLS Annual Report is also available as a PDF document on the LLS Web site, as are all LLS educational programs and printed materials.

LLS has a Co-Pay Assistance Program that is funded entirely with monies from pharmaceutical companies. Total donations to this program from 2007-2009 is just over \$28 million. Patients who meet the income qualifications for the program (500% of the federal poverty level, can qualify for up to \$5,000 per year to subsidize their co-payments for pharmaceuticals, infusions, co-insurance or physician visits related to their treatment for a blood cancer. A copy of the program brochure is attached. For this program, a pharmaceutical company can restrict its support for a specific disease, but not for a specific product or method of administration (oral, infusion or injection). LLS requested an opinion letter from the Office of Inspector General (OIG) to begin this program three years ago. In this letter (attached) the OIG summarized its opinion by stating that LLS had developed a Co-Pay Assistance Program that provided "sufficient insulation so that the Requestor's (LLS) proposed subsidies should not be attributed to any of its donors." The opinion letter goes on to state the: "donors will not be guaranteed that any of their patients, clients, or customers will receive any financial assistance whatsoever from the Requestor (LLS)." For this reason, LLS has chosen to keep all donations to the Co-Pay Assistance Program as anonymous. Patients who apply for funding do not know the identity of corporate donors to the program. Likewise, corporate donors do not know the identity of any patients who receive support from the LLS Co-Pay Assistance Program. Donors to the program are not acknowledged on any printed or electronic materials related to the program. A separate chart for Co-Pay donations is attached that does **not** disclose the individual companies who have made donations to the program. In order to disclose this information, LLS will need to seek guidance from the OIG.

Below are the responses to your specific questions:

1. Please describe the policies for accepting industry funding and whether or not LLS allows companies to place restrictions or provide guidance on how funding will be spent.

The Leukemia & Lymphoma applies for industry funding through grant requests to individual companies. LLS will only accept industry funding that is free of influence as to the content, format or delivery of programs, research, fundraising or public policy outreach. LLS determines all of the content, format and delivery for all of its educational, research, public policy and fundraising programs. This policy is directed by the National Office of The Leukemia & Lymphoma Society and is followed by all LLS chapter offices as well. A copy of a memo to LLS Chapters is attached, which further describes the policy.

2. If LLS allows companies to place restrictions on industry funding, then please explain all restrictions and/or guidance for each transfer of value from industry. For every transfer of value with a restriction, please provide the following information: year of transfer, name of company, and restriction placed on funding.
LLS does not allow companies to place restrictions on industry funding. See above.

3. Please explain what policies, if any that LLS plans to adopt to ensure transparency of funding in order to provide a greater public trust in the independence of its organization.

LLS will continue its policy of disclosing corporate funding sources for all educational, research and fundraising programs. It will continue to identify corporate donors in its Annual Report by funding level. LLS will not disclose funding sources for its Co-Pay Assistance Program, unless it receives additional guidance from the Office of Inspector General.

4. Please explain your policies on disclosure of outside income by your top executives and board members


LLS Board and staff are required to file annual disclosures about conflict of interest. LLS does have three board members who are employed in the pharmaceutical industry. Consistent with the policy, these board members file annual disclosures about conflict of interest. To date, no conflicts have been registered.

5. Please provide the disclosures of outside income filed with your organization by your top executives and board members.

LLS Senior Staff are required to file annual disclosures about conflict of interest. To date, no conflicts have been registered.

We appreciate the opportunity to respond to this inquiry and look forward to answering any questions you may have about our response and supporting documentation. You may reach me directly at 914-821-8822 or via email at john.walter@lls.org.

Sincerely,



John E. Walter
President & CEO

JW:ahc

Attachments:

LLS Listing of Pharmaceutical, Medical Device and Industry Donations 2006-2009
LLS Listing of Pharmaceutical Donations to Co-Pay Assistance Program 2007-2009
Sample Invitation & Programs with disclosure of corporate donor
LLS Annual Report
Letter from Office of Inspector General regarding LLS Co-Pay Assistance Program.
LLS Chapter Memo regarding support from pharmaceutical companies
LLS update on Therapy Acceleration Program

**The Leukemia & Lymphoma Society
National Pharmaceutical Funding FY2006 - FY2010**

FY2006 7/1/05 - 6/30/06				
Company	Program	Dept	Amount Awarded	Award Date
Amgen Inc.	Older Adult Chapter Programs	Patient Services	\$211,000	August-05
Amgen Inc.	Transplant Booklet & Teleconference	Patient Services	\$155,000	November-05
Amgen Inc.	Older Adult, Patient Aid, Journey of Hope, Team in Training	Patient Services & Fundraising	\$200,000	October-05
Amgen Inc.	Mission Day	Public Policy	\$15,000	February-06
Berlex	Journey of Hope Research Awards Dinner 05	Fundraising	\$5,000	July-05
Bristol-Myers Squibb	CML Online Patient Education	Patient Services	\$125,000	July-05
Bristol-Myers Squibb	CML Patient Education	Patient Services	\$448,200	July-05
Bristol-Myers Squibb	Family Support Group Facilitators Training Conference	Patient Services	\$20,000	July-05
Bristol-Myers Squibb	2005	Donor Development	\$25,000	September-05
Bristol-Myers Squibb	06	Donor Development	\$25,000	March-06
Bristol-Myers Squibb	Clinical Trials Chapter Patient Education, AOSW	Patient Services	\$245,000	April-06
Bristol-Myers Squibb	Post ASCO Teleconference	Patient Services	\$200,000	May-06
Bristol-Myers Squibb	CML Global	Patient Services	\$794,000	June-06
Bristol-Myers Squibb	Light The Night Sponsorship - Canada	Fundraising	\$50,000	June-06
Celgene	05	Donor Development	\$25,000	September-05
Celgene	MDS Booklet	Patient Services	\$65,000	August-05
Celgene	MDS Teleconference	Patient Services	\$50,000	October-05
Celgene	Myeloma Teleconference	Patient Services	\$75,000	September-05
Celgene	Exploring Myeloma Teleconference	Patient Services	\$120,000	March-06
Celgene	Myeloma Teleconference Series	Patient Services	\$80,000	March-06
Celgene	MDS-Myeloma Teleconferences	Patient Services	\$130,000	June-06
Celgene	06	Fundraising	\$25,000	June-06
Cephalon	AML Booklet & Teleconference	Patient Services	\$120,000	December-05
Genentech	General Program Support	Fundraising	\$400	September-05
Genentech	Insights - NHL	Patient Services	\$970,000	January-06
Genentech	Light The Night National Sponsorship	Fundraising	\$63,000	January-06
Genta	CLL Teleconference-Web cast	Patient Services	\$200,000	May-06
Genitope	Vaccine Therapy Fact Sheet	Patient Services	\$20,000	August-05
GlaxoSmithKline	Journey of Hope Research Awards Dinner 05	Donor Development	\$10,000	October-05
GlaxoSmithKline	NHL Web cast	Patient Services	\$180,000	July-05
Merck	Mission Day	Public Policy	\$20,000	February-06
Millennium	Journey of Hope Research Awards Dinner 05	Donor Development	\$10,000	July-05
Millennium	Family Support Group Facilitators Training Conference	Patient Services	\$30,000	November-05
Novartis	ALL Low Literacy Booklet	Patient Services	\$65,000	July-05
Novartis	CML Nursing Education	Patient Services	\$449,400	September-05
Novartis	CML Links Teleconference-Web cast	Patient Services	\$445,000	October-05
Novartis	Mission Day	Patient Services	\$10,000	February-06
Pfizer	Information Resource Center Brochure	Patient Services	\$10,000	March-06
Pharmion	MDS Teleconference	Patient Services	\$50,000	July-05
Epsilon	Journey of Hope Research Awards Dinner 05	Donor Development	\$12,500	August-05
Infocision	Journey of Hope Research Awards Dinner 05	Donor Development	\$10,000	August-05

Total Awarded FY06			\$5,763,500	
FY2007 7/1/06 - 6/30/07				
Company	Program	Dept	Amount Awarded	Award Date
Abbott Laboratories	Family Support Group Facilitators Training Conference	Patient Services	\$10,000	December-06
Amgen Inc.	Understanding Transplants Booklet	Patient Services	\$70,000	December-06
Amgen Inc.	Breaking the Age Barrier Teleconference	Patient Services	\$100,000	December-06
Amgen Inc.	Understanding Drug Therapies Booklet	Patient Services	\$70,000	December-06
Amgen Inc.	TNT - Greater LA Chapter	Fundraising	\$25,000	December-06
Amgen Inc.	Journey of Hope Research Awards Dinner 06	Donor Development	\$25,000	October-06
Biogen Idec	CLL Teleconference co-sponsorship	Patient Services	\$50,000	June-07
Biogen Idec	CLL Booklet	Patient Services	\$70,000	February-07
Bristol-Myers Squibb	CML Monitoring Booklet	Patient Services	\$100,000	June-07
Bristol-Myers Squibb	CML Global	Patient Services	\$630,000	December-06
Bristol-Myers Squibb	Clinical Trials Web cast	Patient Services	\$200,000	December-06
Bristol-Myers Squibb	Family Support Group Facilitators Training Conference	Patient Services	\$25,000	December-06
Bristol-Myers Squibb	Patient Navigation	Patient Services	\$150,000	December-06
Bristol-Myers Squibb	Post ASCO CML Teleconference	Patient Services	\$80,000	December-06
Bristol-Myers Squibb	Light The Night National Presenting Sponsor	Fundraising	\$250,000	December-06
Bristol-Myers Squibb	Light The Night National Sponsor - Canada	Fundraising	\$40,000	February-07
Bristol-Myers Squibb	CML Virtual Home	Patient Services	\$100,000	December-06
Celgene	Myeloma-MDS	Patient Services	\$175,000	April-07
Cephalon	CLL Teleconference co-sponsorship	Patient Services	\$50,000	June-07
Cephalon	Journey of Hope Research Awards Dinner 06	Donor Development	\$25,000	August-06
Cephalon	AML Teleconference	Patient Services	\$80,000	January-07
Cephalon	Links & Newslines online Newsletters	Marketing	\$50,000	January-07
Genentech	Meet the Experts - NHL Teleconference	Patient Services	\$175,000	March-07
Genentech	Patient Navigation	Patient Services	\$100,000	March-07
Genentech	Journey of Hope Research Awards Dinner 06	Donor Development	\$10,000	September-06
Genentech	NHL Teleconference Series	Patient Services	\$575,000	February-07
Genentech	NHL Hispanic Outreach	Patient Services	\$80,000	February-07
Genentech	Light The Night National Sponsor	Fundraising	\$100,000	February-07
Genta	Journey of Hope Research Awards Dinner 06	Donor Development	\$10,000	September-06
GlaxoSmithKline	Journey of Hope Research Awards Dinner 06	Donor Development	\$15,000	October-06
GlaxoSmithKline	NHL Teleconference	Patient Services	\$80,000	November-06
Infocision	Journey of Hope Research Awards Dinner 06	Donor Development	\$10,000	September-06
Millennium	Exploring Myeloma Teleconference	Patient Services	\$60,000	April-07
Millennium	Myeloma Links Teleconference Series	Patient Services	\$200,000	December-06
Millennium	Family Support Group Facilitators Training Conference	Patient Services	\$25,000	September-06
Millennium	Journey of Hope Research Awards Dinner 06	Donor Development	\$10,000	July-06
Millennium	Mantle Cell Lymphoma Teleconference	Patient Services	\$80,000	October-06
Millennium	Mantle Cell Lymphoma Fact Sheet	Patient Services	\$25,000	December-06
Millennium	Myeloma Guide Booklet	Patient Services	\$60,000	December-06
Novartis	CML Teleconference Series	Patient Services	\$310,935	May-07
Novartis	Chapter Patient Education Programs	Patient Services	\$100,000	May-07

Novartis	CML Programs	Patient Services	\$835,000	August-06
Novartis	CML Booklet	Patient Services	\$70,000	September-06
Novartis	Chapter Patient Education Programs	Patient Services	\$75,000	November-06
Novartis	Myeloma Booklet	Patient Services	\$70,000	November-06
Novartis	CML Post ASH Web Cast	Patient Services	\$207,000	November-06
Pharmion	MDS Programs & Light The Night Support	Patient Services & Fundraising	\$50,000	July-06
Total Awarded FY07			\$5,707,935	
FY2008 7/1/07-6/30/08				
Company	Program	Dept	Amount Awarded	Award Date
Abbott Laboratories	Family Support Group Facilitators Training	Patient Services	\$25,000	September-07
AmgenMed	Understanding Blood Cell counts Booklet	Patient Services	\$90,000	May-08
AmgenMed	Breaking the Age Barrier Nat'l Chap. Prog.	Patient Services	\$10,000	May-08
Biogen Idec	NHL Journey/Targeted Therapies	Patient Services	\$135,000	July-07
Biogen Idec	CLL Teleconference Series w/newsletters	Patient Services	\$125,000	Dec-07, March-08
Bristol-Myers Squibb	CML Global	Patient Services	\$205,770	April-08
Bristol-Myers Squibb	Post ASCO Teleconference-2008	Patient Services	\$50,000	Jan & April-2008
Bristol-Myers Squibb	CML Personal Journey-2008 Update	Patient Services	\$50,000	Jan & April-2008
Bristol-Myers Squibb	Monitoring booklet and on-line tool	Patient Services	\$50,000	Jan & April-2008
Bristol-Myers Squibb	LTN Nat'l Sponsorship	Fundraising	\$125,000	Jan & April-2008
CDC	Patient Services Programs	Patient Services	\$424,299	September-07
Celgene	Myeloma Links Teleconference Series	Patient Services	\$200,000	May-08
Celgene	New Directions in Myeloma Teleconference	Patient Services	\$100,000	November-36
Celgene	TNT 20th Anniversary Celebration	Fundraising	\$50,000	December-07
Celgene	Myeloma/MDS/Journey of Hope	Patient Services & Donor Development	\$175,000	September-07
Celgene	ACP Program	Patient Services	\$264,000	December-07
Celgene	Advances in Clinical Trials Web cast & Teleconference	Patient Services	\$240,000	January-08
Celgene	Mantel Cell Lymphoma Teleconference	Patient Services	\$100,000	January-08
Cephalon	AML Teleconference Series	Patient Services	\$125,000	February-08
Cephalon	AML Educational Booklets	Patient Services	\$170,000	October-07
Cephalon	Links & Newslines Online newsletters	Marketing	\$50,000	September-07
Cephalon	AML Teleconference Series	Patient Services	\$100,000	September-07
Cephalon	CLL Teleconference Series w/newsletters	Patient Services	\$125,000	February-08
Eli Lilly	My Personal Clinical Trials Journey	Patient Services	\$70,000	Dec-07, Apr-08
Eli Lilly	Journey of Hope Research Awards Dinner 07	Donor Development	\$15,000	September-07
Enzon	ALL Educational Booklet	Patient Services	\$85,000	December-07
Genentech	Insights Series 2008-2009	Patient Services	\$600,000	April-08
Genentech	NHL Journey on-line program, 2nd in series	Patient Services	\$100,000	March-08
Genentech	Patient Navigation	Patient Services	\$100,000	March-08
Genentech	Lymphoma Booklets	Patient Services	\$130,000	March-08
Genentech	Light The Night Nat'l Sponsor	Fundraising	\$100,000	March-08
Genzyme	Post ASH Chapter Leukemia Ed Program	Patient Services	\$25,000	January-08
Genzyme	AML Teleconference Series	Patient Services	\$100,000	January-08
GSK	My Personal Clinical Trials Journey	Patient Services	\$50,000	April-08
GSK	Mission Day	Public Policy	\$10,000	March-08
MGI Pharma	AML Teleconference Series	Patient Services	\$75,000	April-08
Millennium	ASH Satellite Symposium	Patient Services	\$62,500	June-08
Millennium	Career Development Scholar-	Research	\$25,000	March-08
Millennium	Outlook on Myeloma Teleconference Series	Patient Services	\$100,000	February-08

Millennium	Mantel Cell Lymphoma Teleconference	Patient Services	\$200,000	February-08
Millennium	Paving the Way Chapter Program	Patient Services	\$100,000	July-07
Millennium	Journey of Hope Research Awards Dinner 07	Donor Dev	\$100,000	July-07
Millennium	Family Support Group Facilitators Training Conference	Patient Services	\$10,000	January-08
Novartis	Journey of Hope Research Awards Dinner 07	Donor Dev	\$25,000	August-07
Novartis	TNT 20th Anniversary Celebration	Marketing	\$50,000	September-07
Novartis	CML Therapy Webcast Program	Patient Services	\$207,585	October-07
Novartis	Chapter Patient Education Programs	Patient Services	\$75,050	November-07
Novartis	Family Support Group Facilitators Training Conference	Patient Services	\$25,000	November-07
Novartis	Patient Navigation Chapter Program	Patient Services	\$113,375	November-07
Novartis	CML Links Teleconference Series	Patient Services	\$345,000	March-08
Novartis	Patient Navigation	Patient Services	\$156,015	March-08
Novartis	CML Post ASH Webcast & Teleconference	Patient Services	\$282,100	May-08
Novartis	Chapter Patient Education Programs	Patient Services	\$150,000	June-08
Pharmion	MDS Teleconference	Patient Services	\$50,000	July-07
Pharmion	MDS Educational Booklet	Patient Services	\$85,000	January-08
Pharmion	MDS Personal Journey Interactive Web Page	Patient Services	\$140,000	January-08
Regence BCBS	Welcome Back - Pacific Northwest	Patient Services	\$100,000	January-08
TOTAL AWARDS FY2008			\$6,850,694	
FY2009 7/1/08-6/30/09				
Company	Program	Dept	Amount Awarded	Award Date
Allos Therapeutics	CTCL Patient Education Teleconference	Patient Services	\$50,000	May-09
Allos Therapeutics	LLS Newslne & Links e-newsletters	Marketing	\$50,000	March-09
Abbott	Family Support Group Facilitators Training Conference	Patient Services	\$25,000	September-08
Biogen Idec,	CLL Personal Journey	Patient Services	\$80,000	August-08
Bristol-Myers Squibb	The Road to New Discoveries	Patient Services	\$62,500	February & April -09
Bristol-Myers Squibb	Leukemia Online Support Groups	Patient Services	\$25,000	February-09
Bristol-Myers Squibb	Light The Night Nat'l Sponsorship	Marketing	\$62,500	February & April -09
Bristol-Myers Squibb	Journey of Hope Research Awards Dinner 08	Donor Development	\$15,000	July-08
Bristol-Myers Squibb	Light The Night Nat'l Sponsor	Fundraising	\$125,000	September-08
Bristol-Myers Squibb	Post ASCO Teleconference-2008	Patient Services	\$50,000	September-08
Bristol-Myers Squibb	CML Personal Journey-2008 Update	Patient Services	\$50,000	September-08
Bristol-Myers Squibb	Monitoring booklet and on-line	Patient Services	\$50,000	July & September-08
Bristol-Myers Squibb	ASCO Donation Booth	Fundraising	\$10,000	December-08
Celgene	New Dev. in Immunotherapy for FSS ASH	Patient Services	\$50,000	May-09
Celgene	Milestones in Myeloma Therapy Chap. Prog.	Patient Services	\$100,000	May-09
Celgene	Myeloma Teleconf series w/newsletters	Patient Services	\$100,000	May-09
Celgene	Patient Aid Appeal	Patient Services	\$150,000	April-09
Celgene	TrialCheck	Patient Services	\$50,000	April-09
Celgene	Advances in Clinical Trials Teleconference	Patient Services	\$75,000	April-09
Celgene	Mantle Cell Lymphoma Teleconference	Patient Services	\$75,000	March-09
Celgene	ACP Satellite Symposium April 21-25, 2009	Patient Services	\$133,500	February-09
Celgene	MDS Teleconference	Patient Services	\$125,000	November-08

Celgene	Anemia - Clues to a Cancer Diagnosis	Patient Services	\$133,500	September-08
Celgene	Journey of Hope Research Awards Dinner 08	Donor Development	\$15,000	July-08
Cephalon	Light The Night Nat'l Sponsor	Patient Services	\$125,000	March-09
Cephalon	E-Newsletters (Links & Newslines)	Marketing	\$50,000	March-09
Cephalon	AML Teleconference Series w/newsletters	Patient Services	\$125,000	March-09
Cephalon	CLL Teleconference Series	Patient Services	\$125,000	March-09
Cephalon	CLL Personal Journey - interactive web page	Patient Services	\$80,000	January-09
Eisai/MGI Pharma	AML Teleconference Series 08-09	Patient Services	\$62,500	January-09
Eisai Inc.	T-Cell Lymphomas Teleconference	Patient Services	\$25,000	May-09
Eli Lilly & Company	TrialCheck	Patient Services	\$20,000	April-09
Eli Lilly & Company	Journey of Hope Research Awards Dinner 08	Donor Development	\$15,000	October-08
Eli Lilly	Trial Check	Patient Services	\$25,000	August-08
Genentech	Light The Night Nat'l Sponsor	Fundraising	\$125,000	February-09
Genentech	Increased Access to Clinical Trials	Public Policy	\$29,000	June-09
Genentech	NHL Insights Series with newsletters	Patient Services	\$600,000	February-09
Genentech	Patient Navigation	Patient Services	\$100,000	February-09
Genentech	NHL Online Support Group	Patient Services	\$100,000	February-09
Genentech	Online Lymphoma Survivorship	Patient Services	\$100,000	February-09
GlaxoSmithKline	CLL Educational Booklet	Patient Services	\$90,000	April-09
Millennium	TrialCheck FY10	Patient Services	\$25,000	June-09
Millennium	Patient Financial Aid Appeal	Patient Services	\$250,000	June-09
Millennium	Mantle Cell Lymphoma Teleconference	Patient Services	\$75,000	April-09
Millennium	Myeloma Booklets (reg & low literacy)	Patient Services	\$90,000	March-09
Millennium	Family Support Group Facilitators Training Conference	Patient Services	\$25,000	February-09
Millennium	Chapter Block Grant for Professional Education Programs	Patient Services	\$150,000	May-09
Millennium	Myeloma Links Teleconference Series 08/09	Patient Services	\$200,000	February-09
Millennium	Clinical Trials Workshop	Research	\$25,000	February-09
Millennium	Light The Night Nat'l Sponsor	Fundraising	\$125,000	February-09
Millennium	Career Development Scholar II -	Research	\$150,000	January-09
Millennium	Patient Education Programs	Patient Services	\$25,000	July-08
Millennium	New Directions in Myeloma Therapy 08/09	Patient Services	\$100,000	August-08
Millennium	Path to Progress-Clinical Trials 08/09	Patient Services	\$100,000	August-08
Millennium	2008 ASH Satellite Symposium Dec 5	Patient Services	\$128,000	August-08
Millennium	Journey of Hope Research Awards Dinner 08	Donor Development	\$25,000	August-08
Novartis	CML Teleconference Series w/newsletters	Patient Services	\$380,000	April-09
Novartis	Family Support Group Facilitators Training Conference	Patient Services	\$25,000	September-08
Novartis	CML Booklet	Patient Services	\$90,000	November-08
Novartis	CML Low Literacy Booklet	Patient Services	\$90,000	December-08
Novartis	Chapter Grant Patient Ed Programs	Patient Services	\$150,000	December-08
Regence BCBS	Welcome Back - Pacific Northwest	PS & Chap. Campaigns	\$125,000	May-09
Wyeth Pharmaceuticals	Family Support Group Facilitators Training Conference	Patient Services	\$50,000	July-08
Wyeth Pharmaceuticals	Journey of Hope Research Awards Dinner 08	Donor Development	\$15,000	August-08
Total FY2009			\$5,876,500	
FY2010				
7/1/09-6/30/10				
Company	Program	Dept	Amount Awarded	Award Date
Amgen	Understanding Drug Therapy & Managing Side Effects Educational Booklet	Patient Services	\$45,000	August-09

Bristol-Myers Squibb	Light The Night Nat'l Sponsor	Fundraising	\$62,250	July & October-09
Bristol-Myers Squibb	Leukemia Online Support Groups	Patient Services	\$25,000	July-09
Bristol-Myers Squibb	The Road to New Discoveries	Patient Services	\$62,250	July & October-09
Celgene	AAFP Oct. 14-17, 2009	Patient Services	\$50,000	August-09
Celgene	ASCO Donation Station	Fundraising	\$5,000	September-09
Cephalon	AAFP Oct. 2009	Patient Services	\$100,000	November-09
Cephalon	Sales Teams Donation for LTN	Fundraising	\$3,000	September-09
Enzon	ALL Teleconference & Webcast	Patient Services	\$156,602	August-09
Genzyme	Family Support Group Facilitators Training Conference	Patient Services	\$15,000	September-09
Merck	AAFP Oct. 2009	Patient Services	\$20,000	October-09
Millennium	Family Support Group Facilitators Training Conference	Patient Services	\$25,000	November-09
Millennium	MM Patient Access to Healthcare Research	Public Policy	\$357,000	September-09
Millennium	Career Development Scholar I -	Research	\$100,000	August-09
Millennium	Career Development Scholar II	Research	\$50,000	July-09
Millennium	The Road to New Discoveries	Patient Services	\$100,000	July-09
Millennium	Myeloma Teleconf series with newsletters	Patient Services	\$180,000	July-09
Millennium	Milestones in Myeloma Therapy Chap. Prog	Patient Services	\$100,000	July-09
Novartis	CML Post ASH Teleconference	Patient Services	\$100,140	July-09
Novartis	Family Support Group Facilitators Training Conference	Patient Services	\$25,000	September-09
Regence BCBS	Welcome Back Program Pacific Northwest	Patient Services	\$75,000	September-09
Total Awarded FY10			\$1,656,242	
Total 2006-2010			\$25,854,871	